Medtronic PLC (NYSE:MDT) Receives Average Rating of “Moderate Buy” from Brokerages

Medtronic PLC (NYSE:MDT) has been given an average recommendation of “Moderate Buy” by the twenty-six brokerages that are presently covering the stock, MarketBeat.com reports. Ten equities research analysts have rated the stock with a hold recommendation, fifteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $110.8421.

Several brokerages recently commented on MDT. Morgan Stanley upped their target price on Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. Daiwa Securities Group upped their price objective on shares of Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. Robert W. Baird decreased their price objective on shares of Medtronic from $103.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 18th. Leerink Partners dropped their target price on shares of Medtronic from $120.00 to $119.00 and set an “outperform” rating on the stock in a report on Wednesday, February 18th. Finally, Wall Street Zen upgraded Medtronic from a “hold” rating to a “buy” rating in a report on Saturday, February 21st.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic plans to spin off its Diabetes segment via an IPO of MiniMed Group, a move that could unlock value by creating a focused, standalone diabetes business and give investors clearer exposure to high-growth diabetes assets. Medtronic Reshapes Portfolio With MiniMed IPO And Stealth AXiS Approval
• Positive Sentiment: Medtronic’s MiniMed Group is pursuing a U.S. IPO (target ~ $784m), signaling management is executing a portfolio-shaping strategy and potentially accelerating value realization for MDT shareholders. Medtronic’s diabetes business MiniMed looks for $784m in US IPO
• Positive Sentiment: Commercial rollout: Medtronic launched the MiniMed Go Smart MDI system with the Simplera sensor in EMEA — a product that integrates insulin-pen data and continuous sensor data into a single app, expanding commercial reach in diabetes care. This supports recurring-revenue potential in a growth segment. Medtronic begins EMEA commercial launch of MiniMed Go Smart MDI system with Simplera sensor
• Positive Sentiment: Product/clinical beat: Medtronic reported positive findings for its Altaviva tibial neuromodulation therapy for urinary incontinence — a clinical win that can support future commercial adoption in a meaningful urology market. Medtronic reports positive findings for Altaviva tibial neuromod for urinary incontinence
• Neutral Sentiment: Macro/relative performance: Analysts note MDT has underperformed the S&P 500 over the past year, though Wall Street remains moderately constructive — a reminder that valuation and index-relative dynamics could cap upside even as company-specific news is positive. Is Medtronic Stock Underperforming the S&P 500?
• Negative Sentiment: Insider sale: EVP & President Harry “Skip” Kiil sold 52,524 shares (transaction disclosed Feb. 19) for roughly $5.13M at an average price ~ $97.71, reducing his stake by ~61.6%. Large insider dispositions can weigh on sentiment even if they are routine or for diversification/liquidity reasons. Top Medtronic Executive Unloads a Major Chunk of Stock in High-Value Insider Deal

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.26% of the company’s stock.

Institutional Trading of Medtronic

Several hedge funds have recently modified their holdings of MDT. Vanguard Group Inc. increased its stake in Medtronic by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 128,961,343 shares of the medical technology company’s stock valued at $12,388,027,000 after purchasing an additional 1,888,381 shares in the last quarter. State Street Corp increased its position in Medtronic by 2.0% in the 4th quarter. State Street Corp now owns 61,660,158 shares of the medical technology company’s stock valued at $5,966,780,000 after buying an additional 1,199,621 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Medtronic by 2.7% during the 4th quarter. JPMorgan Chase & Co. now owns 53,616,694 shares of the medical technology company’s stock worth $5,150,420,000 after buying an additional 1,419,730 shares during the period. Capital Research Global Investors boosted its holdings in Medtronic by 12.6% in the fourth quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company’s stock worth $3,321,101,000 after acquiring an additional 3,880,174 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Medtronic by 1.1% in the second quarter. Geode Capital Management LLC now owns 28,227,006 shares of the medical technology company’s stock worth $2,448,699,000 after acquiring an additional 310,684 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Medtronic Stock Performance

NYSE MDT opened at $96.97 on Friday. The company has a market capitalization of $124.50 billion, a price-to-earnings ratio of 27.01, a PEG ratio of 2.43 and a beta of 0.71. The company has a quick ratio of 1.80, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. Medtronic has a twelve month low of $79.55 and a twelve month high of $106.33. The stock has a fifty day simple moving average of $98.95 and a 200 day simple moving average of $96.83.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02. The firm had revenue of $9.02 billion for the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts expect that Medtronic will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were paid a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 annualized dividend and a yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is currently 79.11%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).